Jeffrey M Katz1,2,3, Melissa S Eng4, Claire Carrazco5, Anand V Patel5,6, Ram Jadonath7,6, Michele Gribko5, Rohan Arora5,6, Richard B Libman5,6. 1. Departments of Neurology, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA. jkatz2@northwell.edu. 2. Departments of Radiology, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA. jkatz2@northwell.edu. 3. Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. jkatz2@northwell.edu. 4. Feinstein Institute for Medical Research, 300 Community Drive, Manhasset, NY, USA. 5. Departments of Neurology, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA. 6. Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. 7. Departments of Cardiology, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA.
Abstract
OBJECTIVE: To determine the prevalence and risk factors for paroxysmal atrial fibrillation (PAF) diagnosis in non- cryptogenic ischemic stroke (CIS) patients. METHODS: In this pilot-prospective cohort study of non-CIS patients from September 2014 to September 2017, 53 patients were enrolled. 51/53 patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months. Inclusion required diagnosis of a non-AF stroke etiology, age ≥ 40, and either a virtual CHADS2 score ≥ 3 or ≥ 2 PAF-related comorbidities. RESULTS: Over a median monitoring period of 398 days, PAF was detected in 6/51 (11.8%) patients and anticoagulation was initiated in 5/6 (83.3%). Median time to PAF detection was 87 days (range 0-356 days). Median longest PAF episode was 96 min (range 1 to 1122 min), and 4/6 had multiple PAF recordings. Mean left atrial volume index was significantly higher in PAF patients (31.0 vs. 23.2 cc/m2; p = 0.04). CONCLUSION: Long-term monitoring of non-CIS patients detected PAF in a clinically relevant proportion of patients, resulting in stroke prevention therapy optimization. Further study to confirm these findings and refine the subset that would benefit from long-term cardiac monitoring is warranted.
OBJECTIVE: To determine the prevalence and risk factors for paroxysmal atrial fibrillation (PAF) diagnosis in non- cryptogenic ischemic stroke (CIS) patients. METHODS: In this pilot-prospective cohort study of non-CIS patients from September 2014 to September 2017, 53 patients were enrolled. 51/53 patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months. Inclusion required diagnosis of a non-AF stroke etiology, age ≥ 40, and either a virtual CHADS2 score ≥ 3 or ≥ 2 PAF-related comorbidities. RESULTS: Over a median monitoring period of 398 days, PAF was detected in 6/51 (11.8%) patients and anticoagulation was initiated in 5/6 (83.3%). Median time to PAF detection was 87 days (range 0-356 days). Median longest PAF episode was 96 min (range 1 to 1122 min), and 4/6 had multiple PAF recordings. Mean left atrial volume index was significantly higher in PAF patients (31.0 vs. 23.2 cc/m2; p = 0.04). CONCLUSION: Long-term monitoring of non-CIS patients detected PAF in a clinically relevant proportion of patients, resulting in stroke prevention therapy optimization. Further study to confirm these findings and refine the subset that would benefit from long-term cardiac monitoring is warranted.
Authors: Christopher G Favilla; Erin Ingala; Jenny Jara; Emily Fessler; Brett Cucchiara; Steven R Messé; Michael T Mullen; Allyson Prasad; James Siegler; Mathew D Hutchinson; Scott E Kasner Journal: Stroke Date: 2015-04-07 Impact factor: 7.914
Authors: Larry B Goldstein; Cheryl D Bushnell; Robert J Adams; Lawrence J Appel; Lynne T Braun; Seemant Chaturvedi; Mark A Creager; Antonio Culebras; Robert H Eckel; Robert G Hart; Judith A Hinchey; Virginia J Howard; Edward C Jauch; Steven R Levine; James F Meschia; Wesley S Moore; J V Ian Nixon; Thomas A Pearson Journal: Stroke Date: 2010-12-02 Impact factor: 7.914
Authors: Rajeev K Pathak; Adrian Elliott; Melissa E Middeldorp; Megan Meredith; Abhinav B Mehta; Rajiv Mahajan; Jeroen M L Hendriks; Darragh Twomey; Jonathan M Kalman; Walter P Abhayaratna; Dennis H Lau; Prashanthan Sanders Journal: J Am Coll Cardiol Date: 2015-06-22 Impact factor: 24.094
Authors: A J Sanfilippo; V M Abascal; M Sheehan; L B Oertel; P Harrigan; R A Hughes; A E Weyman Journal: Circulation Date: 1990-09 Impact factor: 29.690
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182